Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 9/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.50 |
| ▸ | HTR1A | P08908 | 4/20 | 0.50 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL817421 | 0.84 | HTR2C (0.56) | HTR2CSLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL4878097 | 0.82 | HTR2C (0.53) | HTR2CSLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL28086725 | 0.80 | HTR2C (0.59) | HTR2CSLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL30493303 | 0.78 | HTR2C (0.72) | HTR2CSLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL1006493 | 0.77 | IKBKB (0.53) | HTR2CSLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL7670262 | 0.77 | HTR2C (0.56) | HTR2CSLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL10405257 | 0.77 | HTR2C (0.44) | HTR2CSLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL28243995 | 0.76 | HTR2C (0.53) | HTR2CSLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL10820256 | 0.76 | HTR6 (0.43) | SIGMAR1 | |
| SCHEMBL817723 | 0.75 | HTR2C (0.45) | HTR2CSLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009441-A1 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009441-A1 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | GRM2, GRM1, GRIA2 | HTR2C 36/4885SLC6A2 1294/4885SLC6A4 878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.